

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  <b>INFORMATION DISCLOSURE STATEMENT BY          APPLICANT</b>	ATTY. DOCKET NO.: JCLA21512-R	APPLICATION No.: <b>10/597,813</b>
	APPLICANT: ULRICH BOGDAHN et al.	
	FILING DATE: April 13, 2007	GROUP: 1635

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY	CLASS	SUBCLASS	T
		WO 01/1961	03/22/2001	PCT			✓
		WO 03/056013	07/10/2003	PCT			✓

NON PATENT LITERATURE DOCUMENTS			
EXAMINER INITIAL	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or county where published.	T
		European Search Report of European Application No. 04002846.6-1212, dated on October 21, 2004	✓
		<b>FREDERICK L HALL et al , “Transforming growth factor-<math>\beta</math> type-II receptor signalling: intrinsic/associated casein kinase activity, receptor interactions and functional effects of blocking antibodies”</b> Biochem-J, (1996), Vol. 316, pp. 303-310	✓
		<b>SYLVIANE KOMESLI et al., “Chimeric extracellular domain of type II transforming growth factor (TGF)-<math>\beta</math> receptor fused to the Fc region of human immunoglobulin as a TGF-<math>\beta</math> antagonist”</b> European Journal of Biochemistry, June 15, 1998, Vol. 254, No. 3, pp. 505-513	✓
		<b>PATRICIA LAGADEC et al., “Evidence for Control of Nitric Oxide Synthesis by Intracellular Transforming Growth Factor- <math>\beta</math>1 in Tumor Cells”</b> American Journal of Pathology, Vol. 154, No. 6, June 1999, pp. 1867-1876	✓

EXAMINER	DATE CONSIDERED
----------	-----------------

**EXAMINER:** INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.